|Day Low/High||0.34 / 0.35|
|52 Wk Low/High||0.25 / 1.75|
- Four abstracts selected to be presented on pacritinib highlighting additional safety and long-term follow up data from Phase 3 PERSIST-1 trial -
Additional pacritinib data also presented at AACR
- Five abstracts selected to be presented on pacritinib -
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp.
Law Offices of Howard G. Smith reminds investors of the upcoming April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.
Stocks with insider trader activity include SPTN, FL and CTIC
Stocks with insider trader activity include ATRS, CMT and CTIC
Stocks with insider trader activity include DRE, CTIC and WAFD
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CTI BioPharma Corp.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp.
The law firm of Kirby McInerney LLP announced today that it has been retained by an investor to pursue claims against CTI BioPharma Corp.
Here's a technical look at how to trade some of the most active stocks on Wall Street right now.
Law Offices of Howard G. Smith announces an investigation on behalf of investors of CTI BioPharma Corp.
FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.